Zentalis Pharmaceuticals Llc (NASDAQ: ZNTL) — Perfil da empresa, notícias e dados financeiros
Zentalis Pharmaceuticals focuses on small molecule therapeutics to address various forms of cancer through innovative science.
Zentalis Pharmaceuticals Llc
Zentalis Pharmaceuticals (NASDAQ:ZNTL) is a biopharmaceutical company focused on discovering and developing small molecule therapeutics aimed at addressing various forms of cancer. Leveraging its proprietary technology platforms, Zentalis is working on a pipeline of oncology compounds with the potential to improve the lives of patients by targeting the molecular and genetic drivers of cancer. The company's objective is to push the boundaries of what is possible in cancer treatment by creating medicines that offer new hope and better outcomes. With a focus on rigorous science and a commitment to innovation, Zentalis Pharmaceuticals strives to bring forward novel therapies that address unmet medical needs in the oncology space.
Resumo
Operações
Produtos e/ou serviços de Zentalis Pharmaceuticals Llc
- Development of ZN-c3, a Wee1 inhibitor for treating solid tumors.
- Investigation of ZN-d5, a BCL-2 inhibitor aimed at blood cancers.
- Research on ZN-c5, an oral SERD for estrogen receptor-positive breast cancer.
- Exploration of combination therapies using their proprietary compounds to enhance cancer treatment efficacy.
- Advancing ZN-e4, a candidate for treating non-small cell lung cancer.
- Collaboration on biomarker-driven projects to personalize and improve cancer treatment outcomes.
equipe executiva do Zentalis Pharmaceuticals Llc
- Julie M. EastlandCEO, President & Director
- James B. BucherChief Legal Officer & Corporate Secretary
- Ingmar BrunsChief Medical Officer
- Vincent A. VultaggioSVP of Finance & Principal Accounting Officer
- Robert J. DiVastoChief Technical Officer
- Wendy ChangChief People Officer
- Haibo WangChief Business Officer
- Rajesh IsraniExecutive VP of Regulatory Affairs & Medical Writing
- Henry GuSenior VP & Head of Intellectual Property
- Sarah KellySenior Vice President of Commercial Strategy
Principais indicadores financeiros
Resultados divulgados pela Zentalis Pharmaceuticals Llc, em USD.
- Cap. de mercado
- 194,3 mi
- Receita (TTM)
- 26,9 mi
- P/L
- —
- LPA (diluído, TTM)
- -2.0
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -152,8 mi | -137,1 mi | |
| 67,4 mi | -191,2 mi | -165,8 mi | |
| 0 | -299,5 mi | -292,2 mi | |
| 0 | -227,3 mi | -236,8 mi |